Biotech Values

[genisi]

This news upsets long held belief of mine that raising HDL, at least natural HDL (as opposed to the abnormal HDL particles associated with CETP inhibitors), is beneficial and a promising investment thesis

While these data suggest that HDL raising alone like what dalcetrapib does, has no impact on MI risk, their note here

Of note, at the cholesterol ester transfer protein (CETP) gene, we did find that common genetic variation reduces risk of myocardial infarction by 4%, a result in line with an earlier meta-analysis. However, the CETP variant both increases HDL cholesterol and lowers LDL cholesterol17 in a manner similar to pharmacological inhibitors of CETP. As such, whether the protection afforded by the CETP variant is due to the change in HDL or LDL cholesterol is difficult to distinguish.

Makes me think other CETP inhibitors that also reduce LDL might work. Of course, if we need them at all is a different question.